Valuation: GlaxoSmithKline plc

Market Cap 7.13TCr 9.43TCr 8.38TCr 7.82TCr 13TCr 9,06900Cr 14TCr 95TCr 37TCr 4,63600Cr 35TCr 35TCr 14,87900Cr P/E 2026 *
13.8x
P/E 2027 * 11.4x
Enterprise Value 9.25TCr 12TCr 11TCr 10TCr 17TCr 11,77100Cr 18TCr 1,22900Cr 48TCr 6,01700Cr 46TCr 45TCr 19,31200Cr EV / Sales 2026 *
2.73x
EV / Sales 2027 * 2.53x
Free-Float
92.75%
Yield 2026 *
3.91%
Yield 2027 * 4.21%
Manager TitleAgeSince
Chief Executive Officer 52 01/01/2026
Director of Finance/CFO 64 01/05/2023
Compliance Officer - 01/08/2018
Director TitleAgeSince
Director/Board Member 52 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 67 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%-3.43%+36.07%+115.04% 1,01900Cr
-1.02%-5.60%+35.72%+64.63% 62TCr
+1.11%-0.58%+12.36%+77.95% 46TCr
+0.34%-3.01%+61.79%+41.24% 36TCr
-0.95%-4.05%+20.54%+41.71% 33TCr
-1.46%-2.89%+10.57%+32.81% 27TCr
-1.35%-5.43%-6.17%+8.98% 24TCr
-1.04%-2.79%+35.30%+51.84% 22TCr
-1.87%-4.10%+28.44%+93.66% 18TCr
Average -0.76%-3.39%+26.07%+58.65% 41.08TCr
Weighted average by Cap. -0.60%-3.33%+29.07%+70.57%

Financials

2026 *2027 *
Net sales 3.39TCr 4.49TCr 3.99TCr 3.72TCr 6.4TCr 4,31400Cr 6.46TCr 45TCr 17TCr 2,20500Cr 17TCr 16TCr 7,07800Cr 3.55TCr 4.7TCr 4.17TCr 3.89TCr 6.69TCr 4,51500Cr 6.76TCr 47TCr 18TCr 2,30800Cr 18TCr 17TCr 7,40700Cr
Net income 519.14Cr 686.83Cr 610.25Cr 569.57Cr 979.09Cr 66TCr 988.21Cr 6.89TCr 2.67TCr 34TCr 2.58TCr 2.52TCr 1,08300Cr 620.94Cr 821.51Cr 729.92Cr 681.26Cr 1.17TCr 79TCr 1.18TCr 8.24TCr 3.19TCr 40TCr 3.08TCr 3.02TCr 1,29600Cr
Net Debt 2.12TCr 2.81TCr 2.5TCr 2.33TCr 4.01TCr 2,70200Cr 4.04TCr 28TCr 11TCr 1,38100Cr 11TCr 10TCr 4,43300Cr 1.85TCr 2.45TCr 2.18TCr 2.03TCr 3.49TCr 2,35500Cr 3.52TCr 25TCr 9.53TCr 1,20400Cr 9.2TCr 9TCr 3,86400Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-